



Pfizer Limited

The Capital, 1802/1901,
Plot No. C - 70, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

July 17, 2026

To,

BSE Limited
1st Floor, P.J.Towers
Dalal Street, Fort
Mumbai – 400 001
Scrip Code: 500680

Dear Sirs / Madam,

Sub: Clarification/Confirmation on news item appearing in 'The Hindu Businessline'
<https://www.thehindubusinessline.com/>

We refer to your email Ref.No. L/SURV/ONL/RV/**SG/(2026-2027)/59** dated July 17, 2026, seeking clarification in relation to the news item captioned "Pfizer suspends Premarin vaginal cream in India, raising concerns over menopause care." appearing in *The Hindu BusinessLine*.

In this regard, we wish to submit that Premarin Vaginal Cream, which is an imported product, has been temporarily discontinued in India due to certain supply constraints. The Company is actively exploring options to restore the supply at the earliest.

Please note that Premarin Vaginal Cream contributes less than 1% to the revenue of the Company and the temporary discontinuation is not expected to have any material impact on the Company's financial performance, business operations or profitability.

In view of the above, the temporary discontinuation of the product did not constitute a material event requiring disclosure under Regulation 30 of the SEBI (LODR) Regulations, 2015. The Company remains committed to making timely disclosures of all material events and information in accordance with applicable legal and regulatory requirements.

We trust the above adequately clarifies the matter.

Thanking you,

Yours truly,

For **Pfizer Limited**

Prajeet Nair

Director – Corporate Services & Company Secretary

CIN: L24231MH1950PLC008311

Email ID: contactus.india@pfizer.com

Website: www.pfizerltd.co.in



Pfizer Limited

The Capital, 1802/1901,
Plot No. C - 70, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

July 17, 2026

To,

Mr. Amit Shinde
Chief Manager – Surveillance
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (East), Mumbai – 400 051

Dear Sir,

Sub: Clarification on news item appearing in media publication

We refer to your letter Ref. No. NSE/CM/Surveillance/17278 dated July 17, 2026 seeking clarification in relation to the news item captioned “Pfizer suspends Premarin vaginal cream in India, raising concerns over menopause care.” appearing in The Hindu BusinessLine.

In this regard, we wish to submit that Premarin Vaginal Cream, which is an imported product, has been temporarily discontinued in India due to certain supply constraints. The Company is actively exploring options to restore the supply at the earliest.

Please note that Premarin Vaginal Cream contributes less than 1% to the revenue of the Company and the temporary discontinuation is not expected to have any material impact on the Company’s financial performance, business operations or profitability.

In view of the above, the temporary discontinuation of the product did not constitute a material event requiring disclosure under Regulation 30 of the SEBI (LODR) Regulations, 2015. The Company remains committed to making timely disclosures of all material events and information in accordance with applicable legal and regulatory requirements.

We trust the above adequately clarifies the matter.

Thanking you,

Yours truly,

For **Pfizer Limited**

Prajeet Nair

Director – Corporate Services & Company Secretary

CIN: L24231MH1950PLC008311

Email ID: contactus.india@pfizer.com

Website: www.pfizerltd.co.in